COVID-19 Disease in Children With ALL Receiving Maintenance Therapy: Do Not Discount the Risk
Alissa R. Kahn(Memorial Sloan Kettering Cancer Center), Moran Gotesman(Harbor–UCLA Medical Center), Anurag K. Agrawal, Isaac Martinez(University of Alabama at Birmingham), Christina J. Bemrich‐Stolz, Julienne Brackett(Texas Children's Hospital), Emily E. Johnston(University of Alabama at Birmingham), Julie Wolfson(University of Alabama at Birmingham), Chen Dai(University of Alabama at Birmingham), Emi Caywood(Alfred I. duPont Hospital for Children), Jason Fixler, Jessica Foley(Tufts University), Susan I. Colace(Nationwide Children's Hospital), Aditi Dhir(University of Miami), Shannon M. Cohn, Guillermo De Angulo, Kayleen Bailey, Chana L. Glasser, Elizabeth Davis(University of Alabama at Birmingham), Smita Bhatia(University of Alabama at Birmingham), Scott Coven(Nationwide Children's Hospital), Jenna K. Bardwell, Scott M. Bradfield, Bradley Gampel, Branko Cuglievan(The University of Texas MD Anderson Cancer Center), Carla Schwalm(Bronson Methodist Hospital), Doured Daghistani, Karen S. Fernández(Nationwide Children's Hospital), Anca Silvia Dumitriu, Paula Aristizabal(National Foundation for Cancer Research), David S. Dickens(Albert Einstein College of Medicine), Jessica Goodman, Caroline Caudill(University of Alabama at Birmingham), Jamie L. Dargart, Ann Kebede(Bronson Methodist Hospital), Brook Araya(University of Alabama at Birmingham), Catherine Aftandilian(Stanford University), Asmaa Ferdjallah, Lauren H. Boal(Massachusetts General Hospital), Archana Sharma(Rutgers, The State University of New Jersey), E. Eslin, Stuart Cramer, Catherine W.H. Boston, David L. Becton, Shari L. Feinberg, Joshua Richman(University of Alabama at Birmingham), Jose M. Esquilin, Jennifer Levine(Cornell University)
Cited by 1
Related Papers
Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing Discipline
|Journal of Clinical Oncology|2004|709
Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer
|New England Journal of Medicine|2016|576
Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer
|Clinical Cancer Research|2015|477
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
|Nature Communications|2019|372